
– Hydrolysates, Peptides and Fractions –

December 2015

3A Business Consulting
DAIRY BIOACTIVES TO BE PART OF THE HEALTHY SOLUTION

A new report on dairy-derived bioactives, named The World Market for Dairy Bioactives 2015-2019, clearly demonstrates increasing activity within this business area. The product range continues to expand, more patents are issued, the number of new consumer products launched containing these bioactives is continuously increasing, and the current market size, estimated to more than 55,000 MT with an approximate value of USD 1 billion, is growing by close to 10% p.a. On top of the mentioned figures come galactooligosaccharides representing a high volume market.

The market for dairy bioactives is being driven by the broader nutrition industry, i.e. infant formula, sports nutrition, dietary supplements, clinical nutrition and functional foods.

The major players are the large dairy ingredient companies with significant technological depth and global market reach, e.g. Arla Foods Ingredients, FrieslandCampina, Agropur/Davisco, Glanbia, Fonterra, Ingredia, Murray Goulburn, Carbery, Armor Protéines, Morinaga/Milei and others.

The New Zealand company Tatua is a prominent example of a fairly small player having created a global niche position within bioactives. Relatively new players within this area are some US-based companies such as Hilmar Ingredients and Milk Specialties Global.

“The dairy bioactives business is a high tech, high risk and potentially a high reward business, as it takes considerable knowledge and resources in processing technologies, regulatory aspects including claims and marketing capability to be successful”, says Tage Afferthsholt, Managing Partner in 3A Business Consulting.

The report is global in scope and covers a wide range of ingredients such as milk and whey hydrolysates, peptides, glycomacropeptides, caseinphosphopeptides, α-lactalbumin, β-lactoglobulin, immunoglobulins, lactoferrin, osteopontin, milk phospholipids, galactooligosaccharides (GOS), etc.

Report headlines are:
- Market size (volume and value) and expected growth
- Current applications and new product development trends
- Historical and current price developments
- Producer profiles
- Application and breakdown of end-use segments
- Drivers and barriers
- Regulatory issues
- Patent activity within the given product areas

“Generally, bioactives addressing the current key health issues have excellent growth opportunities, and dairy-derived bioactives will be part of the solution in the future”, says Tage Afferthsholt.
Scope and objectives:

The main objective of this report is to provide the reader with an overview of the current and expected future global market for selected milk and whey fractions and peptides, based on a comprehensive assessment and characterisation of the market, as well as factors directly or indirectly affecting the commercial potential of the selected ingredients.

The areas, which are covered in this respect, are:
- Market size (volume and value) and expected growth
- Current applications and new product development trends
- Historical and current price developments
- Producer profiles
- Application and breakdown of end-use segments
- Drivers and barriers
- Regulatory issues
- Patent activity within the given product areas

The scope and focus of the report is the global market for the following dairy-derived ingredients:
- Hydrolysates
- Milk- and whey-derived peptides
- Lactoferrin
- Lactoperoxidase
- Colostrum/IgG
- α-lactalbumin
- β-lactoglobulin
- Glycomacropeptides
- Galacto-oligossacharides
- Caseinphosphopeptides

Other bioactive ingredients to include:
- Osteopontin
- Milk fat globule membranes
- Bovine serum albumin
- Milk phospholipids

For each ingredient, activity in launched consumer products containing the ingredient has been tracked. Examples are included within the main body of the report, and a more complete listing is provided in the Appendix.

Country coverage:
- Global

Time frame:
- 2015-2019

Price
- The report is available in an electronic and/or hardcopy version and is priced at EUR 4,700.00

Timing
- The report is published December 2015
4.9. $\alpha$-lac ................................................................. 58
  4.9.1. Market overview .................................................. 58
  4.9.2. Market drivers and barriers .................................. 58
  4.9.3. Application and end-user segments ......................... 58
  4.9.4. NPD analysis and product pictures .......................... 61
  4.9.5. Producers ....................................................... 62
4.10. $\beta$-lac ............................................................. 62
  4.10.1. Market overview ................................................ 62
  4.10.2. Market drivers and barriers ................................ 63
  4.10.3. Application and end-user segments ....................... 63
  4.10.4. NPD analysis and product pictures ....................... 63
  4.10.5. Producers ....................................................... 64
4.11. Galacto-oligosaccharides ........................................ 64
  4.11.1. Market overview ................................................ 64
  4.11.2. Market drivers and barriers ................................ 64
  4.11.3. Application and end-user segments ....................... 65
  4.11.4. NPD analysis and product pictures ....................... 65
  4.11.5. Producers ....................................................... 66
4.12. Other dairy bioactives ............................................. 66
  4.12.1. Market overview and drivers and barriers ............... 67
  4.12.2. NPD analysis and product pictures ....................... 68
5. Overview of industry .................................................. 70
  5.1. Company profiles ................................................ 70
  5.2. Acquisitions, mergers and strategic alliances .............. 91
  5.3. Patent situation .................................................. 94
6. Summary and conclusion ................................................ 98
  6.1. Perspective .......................................................... 98
  6.2. Product and market summary .................................... 98
    6.2.1. MPH and WPH .................................................. 98
    6.2.2. Milk and whey peptides .................................... 99
    6.2.3. GMP ............................................................. 99
    6.2.4. CPP ............................................................. 99
    6.2.5. LF ............................................................... 99
    6.2.6. LP ............................................................... 100
    6.2.7. Colostrum ..................................................... 100
    6.2.8. IgG ............................................................. 101
    6.2.9. $\alpha$-lac .................................................... 101
    6.2.10. $\beta$-lac ................................................... 101
    6.2.11. GOS ........................................................... 102
    6.2.12. Other dairy bioactive ingredients ....................... 102
  6.3. NPD overview ..................................................... 103
    6.3.1 Summary of NPD activity of dairy bioactive ingredients .... 103
    6.3.2. NPD activity by key companies ......................... 104
  6.4. Drivers and barriers ............................................... 106
6.4.1. Production costs and technology .......................................................... 106
6.4.2. Supplier concentration and industry structure ..................................... 106
6.4.3. Regulatory issues .............................................................................. 107
6.4.4. Consumer knowledge and acceptance .............................................. 108
6.5. Future market development ................................................................. 110

Appendix
A: Producer/Ingredients summary
B: Consumer product pictures per ingredient
SUBSCRIPTION/ORDER FORM

Please send me □ copy/copies of


---

<table>
<thead>
<tr>
<th>Description</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report (1 hard copy)</td>
<td>□ x EUR 4,700</td>
</tr>
<tr>
<td>Further hard copies at EUR 100 / copy</td>
<td>□ x EUR 100</td>
</tr>
<tr>
<td>Electronic Version (1 user)</td>
<td>□ x EUR 4,700</td>
</tr>
</tbody>
</table>

**SUBTOTAL**

**TOTAL**

**METHOD OF PAYMENT**

☐ Please invoice me on purchase order no. 

☐ I enclose a cheque made payable to 3A Business Consulting

☐ I have arranged a direct bank transfer for the sum of EUR ______ to 3A Business Consulting

---

**Company**  ________________________________ **Name**  ________________________________

**Address**  ________________________________ **VAT No.**  ________________________________

**Tel**  ________________________________ **Fax**  ________________________________

**E-mail**  ________________________________ **www**  ________________________________

**Signed**  ________________________________ **Date**  ________________________________

---

Please fax this order form back to Fax: +45 8613 5066 or send it to 3A Business Consulting, J.M. Moerks Gade 1, DK–8100 Aarhus C, Denmark

For further information please contact Tage Affertsholt by Tel +45 7021 0098 or e-mail ta@3abc.dk